Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Recruiting Phase 1 Interventional

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07619339
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tepotinib, Ivonescimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Not applicable Interventional Results available

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

NCT00104728
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

NCT05740501
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Melanoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Results available

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Combination Product
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Early Phase 1 Interventional Results available

Screening Inhaled Allergen Challenge for Dermatophagoides Farinae

NCT03049111
View directory record Official record
Conditions
Asthma
Interventions
Der f
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT04475939
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Niraparib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Technology- Assisted Stepped Care Intervention Study

NCT03733457
View directory record Official record
Conditions
Asthma
Interventions
Technology-assisted Stepped-care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

NCT00883675
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Docetaxel-Carboplatin
Drug
Lead sponsor
Michael Mann
Network
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

NCT05742607
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
IPH5201 + durvalumab + standard chemotherapy
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
St. Petersburg, Florida • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT02412371
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Paclitaxel, Placebo for Veliparib, Carboplatin, Veliparib, Radiotherapy
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
La Jolla, California • Newark, Delaware • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

NCT02794519
View directory record Official record
Conditions
Asthma
Interventions
Sirukumab, Placebo, Rescue medication
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267
View directory record Official record
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 1 Interventional

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

NCT04007744
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Pembrolizumab, Sonidegib
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Opioid Laws and Pediatric Use

NCT04543227
View directory record Official record
Conditions
Burns, Knee Injuries, Opioid Use, Pain
Interventions
Opioid Use 90-Days Post Treatment
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00073866
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 22, 2026, 10:02 AM EDT
Enrolling by invitation No phase listed Observational

Molecular Analysis of Thoracic Malignancies

NCT01385722
View directory record Official record
Conditions
Thymus Cancer, Thymoma, Thymic Carcinoma, Lung Cancer, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Withdrawn No phase listed Observational

Airway Inflammatory Response During Illness in Children With Respiratory Failure

NCT02047877
View directory record Official record
Conditions
Acute Respiratory Failure, Acute Respiratory Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
20
States / cities
Beverly Hills, California • Glendale, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

NCT02808819
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
52
States / cities
Scottsboro, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma

NCT02241265
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathe Easier II: A Dyad-based Multiple Behavior Intervention

NCT05956782
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
Interventions
Breathe Easier
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00072059
View directory record Official record
Conditions
Anemia, Lung Cancer
Interventions
methoxy polyethylene glycol epoetin beta
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 22, 2026, 10:02 AM EDT